Current Edition


Mirati matches Amgen with updated data for KRAS-blocking cancer drug

Mirati Therapeutics hopes to later this year win U.S. approval of only the second drug able to target tumors spurred by mutations in an elusive …

Continue Reading →
experimental drug

Mirati gives first look at KRAS drug combination in lung cancer

Mirati’s drug, called adagrasib, is particularly closely watched. After Lumakras, which won U.S. approval earlier this year, it’s the most advanced experimental drug targeting a …

Continue Reading →